A systematic review and meta-analysis found that compared with the renin–angiotensin–aldosterone system inhibitor, patients treated with ARNI had lower incidence of composite renal impairment, ESRD, drug discontinuation due to renal events, severe hyperkalemia and a slower eGFR decline [17]. Here, REN is linked to Hyperkalemia.